Hydrix Limited announced it has been selected to develop the control system for Scandinavian Realheart AB's Total Artificial Heart (TAH). Realheart is developing the world's first four-chamber Total Artificial Heart and is publicly listed on the Nasdaq First North Growth Market. This first stage of a multi-stage program will be delivered in financial year 2023 generating revenue of approximately AUD 2 million in that year.

This product development will help accelerate Realheart's TAH system to in-patient clinical trials in 2024. This partnership with Realheart affirms Hydrix's credentials in cardiovascular technology development. The Realheart TAH aims to treat advanced stage heart failure, completely replacing the diseased heart.

The device aims to mimic the function and form of the natural heart, gently circulating blood through the atria and ventricles with its unique atrioventricular plane. The special design aims to minimise the risk of stroke, bleeding, and anaemia, which are common side effects of heart pumps in use today. Hydrix has been providing Mechanical Circulatory Support (MCS) controller development services to companies for more than 10-years.

This includes Ventricular Assist Devices (VAD) that help a struggling heart to pump blood, and Total Artificial Heart (TAH), a complete heart replacement for where a donor heart is unavailable, or unsuitable. Hydrix's skills and experience are an ideal fit for Realheart as they develop the world's first four-chamber total artificial heart.